Trial Completed: Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate (NCT01046487)
WHY IT MATTERS
This completed trial provides important safety and dosing information for doctors considering combination therapy with imatinib and cyclophosphamide for certain cancer patients, potentially improving treatment options.
Researchers completed a study testing two cancer drugs given together: imatinib mesylate and cyclophosphamide. The study involved 26 patients and aimed to find the safest and most effective dose of imatinib mesylate when combined with a fixed dose of cyclophosphamide. This was an early-stage study (Phase 1) to understand how these drugs work together in the body.
NCT ID: NCT01046487 Status: COMPLETED Conditions: Cancer Phase: PHASE1 Enrollment: 26 Sponsor: Centre Oscar Lambret Summary: The purpose of this study is to determine the maximum tolerated dose of imatinib mesylate, given in association with a fixed dose of cyclophosphamide (50 mg bid).